Home › Companies › KALVISTA PHARMACEUTICALS INC. › 2023-2024

KALVISTA PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and KALVISTA PHARMACEUTICALS INC.’s Form 8-K, filed 2023-09-28 (Item 5.07 on EDGAR). Page generated 04 October 2026.

5Ballot items
120Asset managers
749Fund votes
2023-09-26Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore KALVISTA PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by KALVISTA PHARMACEUTICALS INC.

These tallies are KALVISTA PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2023-09-28 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

KALVISTA PHARMACEUTICALS INC. — official shareholder meeting results, meeting held 2023-09-26
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Patrick Treanor	15,931,760	6,722,475	1,058	--	8,184,920	Majority: yes
Elect Director: Edward W. Unkart	15,154,122	7,499,378	1,791	--	8,184,922	Majority: yes
Proposal 2: Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending April 30, 2024:	30,837,741	1,624	848	--	--	Majority: yes
Proposal 3: Approval, on a non-binding advisory basis, of the compensation paid by the Company to its named executive officers:	20,001,348	2,652,134	1,810	--	8,184,921	Majority: yes
Proposal 4: Approval of the Certificate of Amendment to limit the liability of certain officers of the company as permitted pursuant to recent amendments to the Delaware General Corporation Law:	20,203,486	2,450,421	1,385	--	8,184,921	Majority: yes

Source: KALVISTA PHARMACEUTICALS INC., Form 8-K, filed with the SEC on 2023-09-28 — read the filing on EDGAR.

How asset managers voted at the KALVISTA PHARMACEUTICALS INC. 2023-2024 meeting

Each item below shows how the 120 asset managers that disclosed a KALVISTA PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Approval, on a non-binding advisory basis, of the compensation paid by us to our named executive officers as disclosed in the Proxy Statement.

DIRECTOR ELECTIONSCOMPENSATIONMajority of the votes cast: yes

Combines 7 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%12%

FOR: 20,001,348AGAINST: 2,652,134

KALVISTA PHARMACEUTICALS INC.’s own tally for this item (“Proposal 3: Approval, on a non-binding advisory basis, of the compensation paid by the Company to its named executive officers:”): 20,001,348 for, 2,652,134 against, per its Form 8-K filed 2023-09-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 43,215,472 outstanding shares: 46.3% for, 6% against (52.4% of the company cast a for/against vote).

The 118 asset managers below cast 91% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 91%9%

FOR: 91.1%AGAINST: 8.9%NOT VOTED: 0.0%

Largest asset managers voting on “Approval, on a non-binding advisory basis, of the compensation paid by us to our named executive officers as d” at KALVISTA PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
Janus Henderson	15,000,000	0	For
SUVRETTA CAPITAL MANAGEMENT, LLC	0	2,034,506	Against
Vanguard	1,580,767	0	For
Saturn V Capital Management LP	1,520,381	0	For
ADAGE CAPITAL PARTNERS GP, L.L.C.	1,104,339	0	For
BlackRock	863,070	0	For
DRIEHAUS CAPITAL MANAGEMENT LLC	845,909	0	For
MPM BioImpact LLC	761,538	0	For
DAFNA Capital Management LLC	611,032	0	For
Fidelity	577,092	0	For
Citadel	550,065	0	For
SILVERARC CAPITAL MANAGEMENT, LLC	500,462	0	For
GEODE CAPITAL MANAGEMENT, LLC	456,960	0	For
State Street	417,796	0	For
FIRST MANHATTAN CO. LLC.	392,504	0	For
Dimensional	0	390,848	Against
COMMODORE CAPITAL LP	312,553	0	For
Goldman Sachs	257,537	0	For
NAN FUNG TRINITY (HK) Ltd	204,720	0	For
Woodline Partners LP	203,789	0	For
SEI	0	155,185	Against
PARAMETRIC PORTFOLIO ASSOCIATES LLC	147,637	0	For
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND	140,200	0	For
Charles Schwab	130,308	0	For
DE Shaw	102,019	0	For

Showing the 25 largest of 118 asset managers. See all 118 in the interactive database.

2. The election of two Class II directors to hold office until the earliest of our 2026 annual meeting of stockholders and such individual's death, resignation or removal and the election and qualification of his or her successor: PATRICK TREANOR

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

70% Majority: yes · of votes cast

FOR 70%AGAINST 30%

FOR: 15,931,760AGAINST: 6,722,475

KALVISTA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Patrick Treanor”): 15,931,760 for, 6,722,475 against, per its Form 8-K filed 2023-09-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 43,215,472 outstanding shares: 37% for, 16% against (52.4% of the company cast a for/against vote).

The 43 asset managers below cast 67% of the shares they voted on this item FOR (2,573,548 for, 1,256,043 against).

FOR 67%AGAINST 33%

FOR: 2,573,548 (67.2%)AGAINST: 1,256,043 (32.8%)

Largest asset managers voting on “The election of two Class II directors to hold office until the earliest of our 2026 annual meeting of stockho” at KALVISTA PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	1,559,751	0	For
Fidelity	68,059	435,820	Against
BlackRock	485,483	0	For
Dimensional	0	309,247	Against
Goldman Sachs	0	205,266	Against
SEI	77,240	0	For
Equitable	76,147	0	For
Brinker Capital Destinations Trust	0	75,093	Against
DRIEHAUS MUTUAL FUNDS	0	65,664	Against
Charles Schwab	65,154	0	For
TIAA	61,783	0	For
Northern Trust	53,165	0	For
QUANTITATIVE MASTER SERIES LLC	42,833	0	For
RBB FUND, INC.	0	39,035	Against
ALPS ETF Trust	0	25,880	Against
Lincoln Financial	20,500	4,047	For
American Century	0	20,729	Against
T. Rowe Price	17,585	0	For
AIG/SunAmerica	0	12,346	Against
John Hancock	0	10,578	Against
BRIDGEWAY FUNDS INC	0	10,500	Against
Pacific Life	10,379	0	For
Voya	10,369	0	For
Bridge Builder Trust	10,200	0	For
Principal Exchange-Traded Funds	0	7,463	Against

Showing the 25 largest of 43 asset managers. See all 43 in the interactive database.

3. The election of two Class II directors to hold office until the earliest of our 2026 annual meeting of stockholders and such individual's death, resignation or removal and the election and qualification of his or her successor: EDWARD W. UNKART

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

67% Majority: yes · of votes cast

FOR 67%AGAINST 33%

FOR: 15,154,122AGAINST: 7,499,378

KALVISTA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Edward W. Unkart”): 15,154,122 for, 7,499,378 against, per its Form 8-K filed 2023-09-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 43,215,472 outstanding shares: 35% for, 17% against (52.4% of the company cast a for/against vote).

The 43 asset managers below cast 63% of the shares they voted on this item FOR (2,394,420 for, 1,435,171 against).

FOR 63%AGAINST 37%

FOR: 2,394,420 (62.5%)AGAINST: 1,435,171 (37.5%)

Largest asset managers voting on “The election of two Class II directors to hold office until the earliest of our 2026 annual meeting of stockho” at KALVISTA PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	1,559,751	0	For
Fidelity	68,059	435,820	Against
BlackRock	485,483	0	For
Dimensional	0	309,247	Against
Goldman Sachs	0	205,266	Against
SEI	77,240	0	For
Equitable	43,737	32,410	For
Brinker Capital Destinations Trust	0	75,093	Against
DRIEHAUS MUTUAL FUNDS	0	65,664	Against
Charles Schwab	65,154	0	For
TIAA	0	61,783	Against
Northern Trust	0	53,165	Against
QUANTITATIVE MASTER SERIES LLC	42,833	0	For
RBB FUND, INC.	0	39,035	Against
ALPS ETF Trust	0	25,880	Against
Lincoln Financial	0	24,547	Against
American Century	0	20,729	Against
T. Rowe Price	17,585	0	For
AIG/SunAmerica	0	12,346	Against
John Hancock	0	10,578	Against
BRIDGEWAY FUNDS INC	0	10,500	Against
Pacific Life	10,379	0	For
Voya	10,369	0	For
Bridge Builder Trust	10,200	0	For
Principal Exchange-Traded Funds	0	7,463	Against

Showing the 25 largest of 43 asset managers. See all 43 in the interactive database.

4. The ratification of the selection, by the audit committee of our Board, of Deloitte & Touche LLP as our independent registered public accounting firm for the year ending April 30, 2024.

DIRECTOR ELECTIONSAUDIT-RELATEDMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 30,837,741AGAINST: 1,624

KALVISTA PHARMACEUTICALS INC.’s own tally for this item (“Proposal 2: Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending April 30, 2024:”): 30,837,741 for, 1,624 against, per its Form 8-K filed 2023-09-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 43,215,472 outstanding shares: 71% for, 0.1% against (71% of the company cast a for/against vote).

The 43 asset managers below cast 100% of the shares they voted on this item FOR (3,829,591 for, 0 against).

FOR 100%

FOR: 3,829,591 (100.0%)

Largest asset managers voting on “The ratification of the selection, by the audit committee of our Board, of Deloitte & Touche LLP as our indepe” at KALVISTA PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Vote
Vanguard	1,559,751	For
Fidelity	503,879	For
BlackRock	485,483	For
Dimensional	309,247	For
Goldman Sachs	205,266	For
SEI	77,240	For
Equitable	76,147	For
Brinker Capital Destinations Trust	75,093	For
DRIEHAUS MUTUAL FUNDS	65,664	For
Charles Schwab	65,154	For
TIAA	61,783	For
Northern Trust	53,165	For
QUANTITATIVE MASTER SERIES LLC	42,833	For
RBB FUND, INC.	39,035	For
ALPS ETF Trust	25,880	For
Lincoln Financial	24,547	For
American Century	20,729	For
T. Rowe Price	17,585	For
AIG/SunAmerica	12,346	For
John Hancock	10,578	For
BRIDGEWAY FUNDS INC	10,500	For
Pacific Life	10,379	For
Voya	10,369	For
Bridge Builder Trust	10,200	For
Principal Exchange-Traded Funds	7,463	For

Showing the 25 largest of 43 asset managers. See all 43 in the interactive database.

5. Approval of a Certificate of Amendment to our Amended and Restated Certificate of Incorporation to limit the liability of certain officers as permitted pursuant to recent amendments to the Delaware General Corporation Law.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%11%

FOR: 20,203,486AGAINST: 2,450,421

KALVISTA PHARMACEUTICALS INC.’s own tally for this item (“Proposal 4: Approval of the Certificate of Amendment to limit the liability of certain officers of the company as permitted pursuant to recent amendments to the Delaware General Corporation Law:”): 20,203,486 for, 2,450,421 against, per its Form 8-K filed 2023-09-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 43,215,472 outstanding shares: 46.8% for, 6% against (52.4% of the company cast a for/against vote).

The 43 asset managers below cast 96% of the shares they voted on this item FOR (3,687,197 for, 142,394 against).

FOR 96%

FOR: 3,687,197 (96.3%)AGAINST: 142,394 (3.7%)

Largest asset managers voting on “Approval of a Certificate of Amendment to our Amended and Restated Certificate of Incorporation to limit the l” at KALVISTA PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	1,559,751	0	For
Fidelity	503,879	0	For
BlackRock	485,483	0	For
Dimensional	309,247	0	For
Goldman Sachs	205,266	0	For
SEI	0	77,240	Against
Equitable	76,147	0	For
Brinker Capital Destinations Trust	75,093	0	For
DRIEHAUS MUTUAL FUNDS	65,664	0	For
Charles Schwab	0	65,154	Against
TIAA	61,783	0	For
Northern Trust	53,165	0	For
QUANTITATIVE MASTER SERIES LLC	42,833	0	For
RBB FUND, INC.	39,035	0	For
ALPS ETF Trust	25,880	0	For
Lincoln Financial	24,547	0	For
American Century	20,729	0	For
T. Rowe Price	17,585	0	For
AIG/SunAmerica	12,346	0	For
John Hancock	10,578	0	For
BRIDGEWAY FUNDS INC	10,500	0	For
Pacific Life	10,379	0	For
Voya	10,369	0	For
Bridge Builder Trust	10,200	0	For
Principal Exchange-Traded Funds	7,463	0	For

Showing the 25 largest of 43 asset managers. See all 43 in the interactive database.

Largest KALVISTA PHARMACEUTICALS INC. shareholders voting in 2023-2024

Ranked by the number of KALVISTA PHARMACEUTICALS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 43,215,472 shares outstanding at the time of that meeting.

Top KALVISTA PHARMACEUTICALS INC. shareholders by shares voted, 2023-2024
#	Asset manager	% of shares outstanding
1	Janus Henderson	34.71%
2	SUVRETTA CAPITAL MANAGEMENT, LLC	4.71%
3	Vanguard	3.66%
4	Saturn V Capital Management LP	3.52%
5	ADAGE CAPITAL PARTNERS GP, L.L.C.	2.56%
6	BlackRock	2.00%
7	DRIEHAUS CAPITAL MANAGEMENT LLC	1.96%
8	MPM BioImpact LLC	1.76%
9	DAFNA Capital Management LLC	1.41%
10	Fidelity	1.34%

Reported KALVISTA PHARMACEUTICALS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

KALVISTA PHARMACEUTICALS INC. beneficial owners on record for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
Entities affiliated with Venrock Healthcare Capital Partners III, L.P.	11.16%	DEF14A
S	10.02%	13G
Entities affiliated with Frazier Life Sciences Public Fund, L.P.	8.53%	DEF14A
Tang Capital Partners, LP	7.96%	DEF14A
BlackRock	7.23%	13F
Adage Capital Partners, L.P.	6.58%	DEF14A
Entities affiliated with Suvretta Capital Management, LLC	6.21%	DEF14A
Vanguard Group	5.79%	13F
Albert Cha	5.06%	DEF14A
Goldman Sachs	4.17%	13F

Percentages above are of 43,215,472 shares outstanding, as reported by KALVISTA PHARMACEUTICALS INC. on its Form 10-Q dated 2024-08-26 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from KALVISTA PHARMACEUTICALS INC.’s 10-Q dated 2024-08-26. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At KALVISTA PHARMACEUTICALS INC.'s shareholder meeting held 2023-09-26, in the 2023-2024 proxy season, 120 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 749 separate fund positions. On the most widely held item on that ballot — Approval, on a non-binding advisory basis, of the compensation paid by us to our named… — FOR was 88% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: KALVISTA PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2023-09-28.

KALVISTA PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.